Safety profile for PEMAZYRE — 1 of 1

The safety profile of PEMAZYRE was investigated in the FIGHT–202 study

In FIGHT-202, the most common AR observed with PEMAZYRE was hyperphosphataemia1

  • The safety of PEMAZYRE was investigated in the FIGHT–202 study in previously treated patients with CCA (N=147)1,27

Serious ARs

Selected ARs

Special Warnings and
Precautions for use

For further safety information, please refer to the PEMAZYRE Summary of Product Characteristics.1

Healthcare professionals are asked to report any suspected ARs via the Yellow Card Scheme. Visit or search for MHRA Yellow Card in the Google Play or Apple App Store.1 Adverse events should also be reported to Incyte immediately by phoning 0330-100-3677 (Great Britain) or 00-800-0002-7423 (United Kingdom [Northern Ireland]).

PEMAZYRE (>15%)1,27

Bar chart showing common ARs observed with PEMAZYRE

Patients (%)

Most common ARs (any grade)